Meeting
2011 ASCO Annual Meeting
Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer.
Authors
E. Van Cutsem
University Hospital Gasthuisberg, Leuven, Belgium
E. Van Cutsem , C. Boni , J. Tabernero , B. Massuti , D. A. Richards , H. Prenen , I. Steinberg , P. Rougier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal, Gastric, or Small Bowel
Clinical Trial Registration Number
NCT00382720
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4018)
Abstract #
4018
Poster Bd #
11
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Infusional fluorouracil and weekly docetaxel as first-line therapy for gastric cancer with bone marrow metastasis and disseminated intravascular coagulation: A multi-center, phase II trial (Zhen Long).
First Author: Jian Xiao
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
First Author: Hiroyuki Arai
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
First Author: Manish A. Shah